Interventional Technologies
PerQsealHero7_Tag_Hex-1

Close with confidence.

Don’t complicate it.

One device and done. Over-the-wire delivery with no preclose or preprocedural steps. Deploy at the end of the primary procedure. Leave nothing permanent behind. 0% major complications per VARC-3.1

Confirm before you commit.

Repositionable and recoverable.* Maintain wire access until hemostasis is verified, prior to implant release.

Near-instant hemostasis. Mean time to achieve hemostasis is < 1 minute.1

Respect the vessel.

Patch, don’t pinch. Close with no sutures, no purse-string effect.

100% bioabsorbable. Leave nothing permanent behind. Vessel expected to return to its natural state within ~180 days.

PacePro_Hero1_Web_Tag

More than a feeling.

Engineered to perform.

  • Consistent control. Uniform stability through every TAVR twist and turn. From sheath insertion through valve delivery.
  • Pre-formed spiral tip. Designed for reliable ventricular positioning, dependable contact, superior tip retention and controlled tip load.
  • 280 cm length. Stays in-hand throughout deployment. Designed to support continuous procedural control, increased control for taller patients, and backup pacing after valve placement.

Cleared to pace.

  • On label, on purpose. FDA-cleared for temporary intracardiac pacing. Designed and labeled for LV use.
  • No kitting. Valve delivery and pacing combine in one wire. No need for a separate pacing catheter, venous access or disposable pacing kit.
  • Don’t scrape by. PTFE-sleeved shaft, low-resistance design, and defined pacing zones that deliver current directly to the ventricle — no manual workarounds required.
SavvyHero1
WordMarks_OL_Sized_Savvy_Long

Designed for the moment of truth.

  • Performance. High performance TAVI wire that provides dependability and stability throughout the entire procedure
  • Pacing. Confidence and control to help optimize LV pacing throughout valve deployment
  • Pressure. Continuous, invasive hemodynamic feedback that enables efficiencies pre- to post-valve implantation
OptoWireHero1
WordMarks_OL_Sized_Opto_Long

The way physiology should be.

  • Designed with the feel and performance you need to reach the lesion, from simple to complex.
  • Accurate physiologic measurements with second-generation proprietary fiber optic sensor technology.
  • Allows you to diagnose, treat and complete with one wire.
OptoMonitor-15inch_RightAngle_2331
WordMarks_OL_Sized_OptoMonitor

Interventional cardiology in a whole new LIGHT.

  • Integrated: DICOM connectivity for receiving and exporting data to PACS.
  • Versatile: Small footprint and several configuration options.
  • Adaptable: Different monitor sizes available for tableside or control room use.
  • Intuitive: Touchscreen interface with crisp images and straightforward annotations.
Vascade
WordMarks_OL_Sized_Vascade

Safe. Simple. Proven.

5-7F ID Femoral Arterial & Venous Closure System

  • Enables rapid hemostasis while minimizing access site complications.
  • Elegantly simple, three-step deployment.
  • Only extravascular closure system to offer collagen with a dual method of action, mechanical and physiological.
VascadeMVP
WordMarks_OL_Sized_VascadeMVP

Early ambulation starts here.

6-12F ID, 15F max OD Femoral Venous Closure System

  • Combines collapsible-disc technology with thrombogenic resorbable extravascular collagen plug.
  • 23F diameter disc.
  • 12 mg collagen.
  • 2.2 hours median time to ambulation.2
  • 51% reduction in pain medication.3
  • 58% reduction in opioid use.3
  • 63% improvement in patient satisfaction.3
  • 0% major complications in >1,000 patients in 5 EP clinical trials.†3-7
VascadeMVPXL
WordMarks_OL_Sized_VascadeMVPXL

Simply bigger.

10-14F ID, 17F max OD Femoral Venous Closure System

  • Combines collapsible-disc technology with thrombogenic resorbable extravascular collagen plug.
  • 25F diameter disc.
  • 19mg collagen (58% more than VASCADE MVP® system).
  • 2.3 minutes median time to hemostasis.8
  • 2.4 hours median time to ambulation.8‡
  • 2.7 hours median time to discharge eligibility.8
  • 4.7 hours median time to discharge.8
  • 0% major and minor complications.8†§

Want a product demo? More information?

Contact us about Haemonetics Interventional Technologies.

* Repositionable and recoverable prior to implant release

† Major venous access site closure-related complications through 30-day follow up

‡ In Per Protocol population (N=66)

§ Minor venous access site closure-related complications through 30-day follow up

1. Results from the prospective, single-arm, multi-center ELITE arterial study; VARC-3 major device-related vascular access site complications (adjudicated) through 30 days. See PerQseal® Elite instructions for use (DP4-C56-5). 
2. VASCADE MVP IFU 3972.
3. Compared to Manual Compression. Natale A, et al. Venous vascular closure system versus manual compression following multiple access electrophysiology procedures: The AMBULATE Trial. JACC Clin Electrophysiol October 2019. DOI: 10.1016/j.jacep.2019.08.013.
4. Al-Ahmad A, et al. Results from the prospective, multicenter AMBULATE-CAP trial: Reduced use of urinary catheters and protamine with hemostasis via the mid-bore venous vascular closure system (Vascade MVP) following multi-access cardiac ablation procedures. J Cardiovasc Electrophysiol Dec 2020. https://doi.org/10.1111/jce.14828. NCT03573206.
5. AMBULATE Same Day Discharge Registry Retrospective Study: NCT04538781.
6-7. Eldadah ZA, et al. Same-day discharge following catheter ablation and venous closure with VASCADE MVP: A post-market registry. J Cardioavasc Electrophsyiol 2022. https://doi.org/10.1111/jce.15763 NCT04203329.
8. VASCADE MVP XL IFU 4911.

COL-COPY-002875-US(AA)